These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2973485)

  • 1. The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty.
    de Bono DP
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):20A-23A. PubMed ID: 2973485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
    de Bono DP
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
    Arnold AE; Simoons ML; Van de Werf F; de Bono DP; Lubsen J; Tijssen JG; Serruys PW; Verstraete M
    Circulation; 1992 Jul; 86(1):111-20. PubMed ID: 1617763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    TIMI Study Group
    N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
    Califf RM; Topol EJ; George BS; Boswick JM; Lee KL; Stump D; Dillon J; Abbottsmith C; Candela RJ; Kereiakes DJ
    Circulation; 1988 May; 77(5):1090-9. PubMed ID: 2966016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial.
    Williams DO; Ruocco NA; Forman S
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):45B-50B. PubMed ID: 2959715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
    Simoons ML; Arnold AE; Betriu A; de Bono DP; Col J; Dougherty FC; von Essen R; Lambertz H; Lubsen J; Meier B
    Lancet; 1988 Jan; 1(8579):197-203. PubMed ID: 2893037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial.
    Topol EJ; Califf RM; Kereiakes DJ; George BS
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):65B-74B. PubMed ID: 2959716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
    Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
    J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome.
    Grines CL; Topol EJ; Bates ER; Juni JE; Walton JA; O'Neill WW
    Am Heart J; 1988 Jan; 115(1 Pt 1):1-7. PubMed ID: 2962478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
    Vahanian A
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():39-43. PubMed ID: 2973300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials.
    Topol EJ; Califf RM; George BS; Kereiakes DJ; Lee KL
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):24A-31A. PubMed ID: 2973486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Barbash GI; Roth A; Hod H; Modan M; Miller HI; Rath S; Zahav YH; Keren G; Motro M; Shachar A
    Am J Cardiol; 1990 Sep; 66(5):538-45. PubMed ID: 2118299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator.
    Ellis SG; Topol EJ; George BS; Kereiakes DJ; Debowey D; Sigmon KN; Pickel A; Lee KL; Califf RM
    Circulation; 1989 Nov; 80(5):1159-65. PubMed ID: 2509102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
    Topol EJ; Califf RM; George BS; Kereiakes DJ; Abbottsmith CW; Candela RJ; Lee KL; Pitt B; Stack RS; O'Neill WW
    N Engl J Med; 1987 Sep; 317(10):581-8. PubMed ID: 2956516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
    Van de Werf F; Arnold AE
    BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality.
    Bates ER; Califf RM; Stack RS; Aronson L; George BS; Candela RJ; Kereiakes DJ; Abbottsmith CW; Anderson L; Pitt B
    J Am Coll Cardiol; 1989 Jan; 13(1):12-8. PubMed ID: 2521226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.
    Passamani E; Hodges M; Herman M; Grose R; Chaitman B; Rogers W; Forman S; Terrin M; Knatterud G; Robertson T
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):51B-64B. PubMed ID: 2889758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group.
    Arnold AE; Serruys PW; Rutsch W; Simoons ML; de Bono DP; Tijssen JG; Lubsen J; Verstraete M
    J Am Coll Cardiol; 1991 Jan; 17(1):11-21. PubMed ID: 1898951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.